You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


AZ’s Imfinzi fails to improve overall survival in head and neck cancer again

AstraZeneca’s Imfinzi has failed to improved overall survival (OS) in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) for the second time.